Paulo Ricardo Marques Filho1, Rafael Vercelino2, Stefania Giotti Cioato1, Liciane Fernandes Medeiros3, Carla de Oliveira1, Vanessa Leal Scarabelot2, Andressa Souza4, Joanna Ripoll Rozisky5, Alexandre da Silva Quevedo4, Lauren Naomi Spezia Adachi1, Paulo Roberto S Sanches6, Felipe Fregni7, Wolnei Caumo8, Iraci L S Torres9. 1. Post-Graduate Program in Medicine: Medical Sciences - Medicine School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS 90035-003, Brazil; Pharmacology of Pain and Neuromodulation Laboratory: Pre-clinical Researches Department of Pharmacology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil; Animal Experimentation Unit and Graduate Research Group, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035-003, Brazil. 2. Pharmacology of Pain and Neuromodulation Laboratory: Pre-clinical Researches Department of Pharmacology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil; Animal Experimentation Unit and Graduate Research Group, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035-003, Brazil; Post-Graduate Program in Biological Sciences - Physiology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil. 3. Pharmacology of Pain and Neuromodulation Laboratory: Pre-clinical Researches Department of Pharmacology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil; Animal Experimentation Unit and Graduate Research Group, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035-003, Brazil; Post-Graduate Program in Biological Sciences: Pharmacology and Experimental Therapeutic, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil. 4. Pharmacology of Pain and Neuromodulation Laboratory: Pre-clinical Researches Department of Pharmacology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil. 5. Post-Graduate Program in Medicine: Medical Sciences - Medicine School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS 90035-003, Brazil; Animal Experimentation Unit and Graduate Research Group, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035-003, Brazil. 6. Biomedical Engineering of Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035-003, Brazil. 7. Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 8. Post-Graduate Program in Medicine: Medical Sciences - Medicine School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS 90035-003, Brazil. 9. Post-Graduate Program in Medicine: Medical Sciences - Medicine School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS 90035-003, Brazil; Pharmacology of Pain and Neuromodulation Laboratory: Pre-clinical Researches Department of Pharmacology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil; Animal Experimentation Unit and Graduate Research Group, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS 90035-003, Brazil; Post-Graduate Program in Biological Sciences - Physiology, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil; Post-Graduate Program in Biological Sciences: Pharmacology and Experimental Therapeutic, Universidade Federal do Rio Grande do Sul, ICBS, Porto Alegre, RS 90050-170, Brazil. Electronic address: iracitorres@gmail.com.
Abstract
INTRODUCTION: Neuropathic pain (NP) is a chronic pain modality that usually results of damage in the somatosensory system. NP often shows insufficient response to classic analgesics and remains a challenge to medical treatment. The transcranial direct current stimulation (tDCS) is a non-invasive technique, which induces neuroplastic changes in central nervous system of animals and humans. The brain derived neurotrophic factor plays an important role in synaptic plasticity process. Behavior changes such as decreased locomotor and exploratory activities and anxiety disorders are common comorbidities associated with NP. OBJECTIVE: Evaluate the effect of tDCS treatment on locomotor and exploratory activities, and anxiety-like behavior, and peripheral and central BDNF levels in rats submitted to neuropathic pain model. METHODS: Rats were randomly divided: Ss, SsS, SsT, NP, NpS, and NpT. The neuropathic pain model was induced by partial sciatic nerve compression at 14 days after surgery; the tDCS treatment was initiated. The animals of treated groups were subjected to a 20 minute session of tDCS, for eight days. The Open Field and Elevated Pluz Maze tests were applied 24 h (phase I) and 7 days (phase II) after the end of tDCS treatment. The serum, spinal cord, brainstem and cerebral cortex BDNF levels were determined 48 h (phase I) and 8 days (phase II) after tDCS treatment by ELISA. RESULTS: The chronic constriction injury (CCI) induces decrease in locomotor and exploratory activities, increases in the behavior-like anxiety, and increases in the brainstem BDNF levels, the last, in phase II (one-way ANOVA/SNK, P<0.05 for all). The tDCS treatment already reverted all these effects induced by CCI (one-way ANOVA/SNK, P<0.05 for all). Furthermore, the tDCS treatment decreased serum and cerebral cortex BDNF levels and it increased these levels in the spinal cord in phase II (one-way ANOVA/SNK, P<0.05). CONCLUSION: tDCS reverts behavioral alterations associated to neuropathic pain, indicating possible analgesic and anxiolytic tDCS effects. tDCS treatment induces changes in the BDNF levels in different regions of the central nervous system (CNS), and this effect can be attributed to different cellular signaling activations.
INTRODUCTION:Neuropathic pain (NP) is a chronic pain modality that usually results of damage in the somatosensory system. NP often shows insufficient response to classic analgesics and remains a challenge to medical treatment. The transcranial direct current stimulation (tDCS) is a non-invasive technique, which induces neuroplastic changes in central nervous system of animals and humans. The brain derived neurotrophic factor plays an important role in synaptic plasticity process. Behavior changes such as decreased locomotor and exploratory activities and anxiety disorders are common comorbidities associated with NP. OBJECTIVE: Evaluate the effect of tDCS treatment on locomotor and exploratory activities, and anxiety-like behavior, and peripheral and central BDNF levels in rats submitted to neuropathic pain model. METHODS:Rats were randomly divided: Ss, SsS, SsT, NP, NpS, and NpT. The neuropathic pain model was induced by partial sciatic nerve compression at 14 days after surgery; the tDCS treatment was initiated. The animals of treated groups were subjected to a 20 minute session of tDCS, for eight days. The Open Field and Elevated Pluz Maze tests were applied 24 h (phase I) and 7 days (phase II) after the end of tDCS treatment. The serum, spinal cord, brainstem and cerebral cortex BDNF levels were determined 48 h (phase I) and 8 days (phase II) after tDCS treatment by ELISA. RESULTS: The chronic constriction injury (CCI) induces decrease in locomotor and exploratory activities, increases in the behavior-like anxiety, and increases in the brainstem BDNF levels, the last, in phase II (one-way ANOVA/SNK, P<0.05 for all). The tDCS treatment already reverted all these effects induced by CCI (one-way ANOVA/SNK, P<0.05 for all). Furthermore, the tDCS treatment decreased serum and cerebral cortex BDNF levels and it increased these levels in the spinal cord in phase II (one-way ANOVA/SNK, P<0.05). CONCLUSION: tDCS reverts behavioral alterations associated to neuropathic pain, indicating possible analgesic and anxiolytic tDCS effects. tDCS treatment induces changes in the BDNF levels in different regions of the central nervous system (CNS), and this effect can be attributed to different cellular signaling activations.
Authors: Tiago da Silva Lopes; Wellington Dos Santos Silva; Sânzia B Ribeiro; Camila A Figueiredo; Fernanda Q Campbell; Gildasio de Cerqueira Daltro; Antônio Valenzuela; Pedro Montoya; Rita de C S Lucena; Abrahão F Baptista Journal: Front Hum Neurosci Date: 2017-12-20 Impact factor: 3.169
Authors: Ana Sánchez-Kuhn; Cristian Pérez-Fernández; Rosa Cánovas; Pilar Flores; Fernando Sánchez-Santed Journal: Biomed Eng Online Date: 2017-08-18 Impact factor: 2.819
Authors: Daniela Silva Santos; Bettega Costa Lopes; Liciane Fernandes Medeiros; José Antônio Fagundes Assumpção; Andressa de Souza; Artur Alban Salvi; Lisiane Santos da Silva; Felipe Fregni; Wolnei Caumo; Iraci L S Torres Journal: Neurochem Res Date: 2020-08-25 Impact factor: 3.996
Authors: Larisse Longo; Valessa Emanoele Gabriel de Souza; Dirson João Stein; Joice Soares de Freitas; Carolina Uribe-Cruz; Iraci L S Torres; Mário Reis Álvares-da-Silva Journal: Sci Rep Date: 2021-05-26 Impact factor: 4.379